176 related articles for article (PubMed ID: 1667534)
1. NZ-105, a new 1,4-dihydropyridine derivative: correlation between dihydropyridine receptor binding and inhibition of calcium uptake in rabbit aorta.
Yamashita T; Masuda Y; Sakai T; Tanaka S; Kasuya Y
Jpn J Pharmacol; 1991 Nov; 57(3):337-48. PubMed ID: 1667534
[TBL] [Abstract][Full Text] [Related]
2. Vasorelaxing and receptor binding properties of NZ-105, a novel dihydropyridine derivative, in isolated rabbit aorta.
Masuda Y; Iwama T; Yamashita T; Sakai T; Hibi M; Tanaka S; Shigenobu K; Kasuya Y
Arch Int Pharmacodyn Ther; 1991; 312():86-103. PubMed ID: 1663336
[TBL] [Abstract][Full Text] [Related]
3. Cardiac and vascular effects of NZ-105, a novel dihydropyridine derivative, in vitro.
Masuda Y; Iwama T; Yamashita T; Sakai T; Hibi M; Tanaka S; Shigenobu K; Kasuya Y
Arch Int Pharmacodyn Ther; 1991; 314():57-73. PubMed ID: 1668604
[TBL] [Abstract][Full Text] [Related]
4. Calcium channel blocking and vasodilating actions of the novel dihydropyridine derivative AE0047.
Nishikawa M; Gohda M; Shinyama H; Matzno S; Yamanaga K; Kido H; Nakamura N
Clin Exp Pharmacol Physiol; 1998 May; 25(5):347-54. PubMed ID: 9612662
[TBL] [Abstract][Full Text] [Related]
5. Radioligand and functional estimates of the interaction of the 1,4-dihydropyridines, isradipine and lacidipine, with calcium channels in smooth muscle.
Salomone S; Godfraind T
Br J Pharmacol; 1993 May; 109(1):100-6. PubMed ID: 8495233
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of 3H-nitrendipine binding in rat aortic and cerebral cortex membranes by the new dihydropyridine calcium antagonist benidipine hydrochloride.
Ishii A
Arzneimittelforschung; 1989 Dec; 39(12):1546-50. PubMed ID: 2624603
[TBL] [Abstract][Full Text] [Related]
7. Effects of a new dihydropyridine calcium antagonist on vascular smooth muscles, cardiac muscles and [3H]-nitrendipine binding.
Miura A; Ukai Y; Matsuzaki T; Taniguchi N; Hayashi S; Kano S; Kimura Y; Kimura K; Enomoto H
Arzneimittelforschung; 1986 Sep; 36(9):1323-8. PubMed ID: 3790181
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular selectivity of 1,4-dihydropyridine derivatives, efonidipine (NZ-105), nicardipine and structure related compounds in isolated guinea-pig tissues.
Masuda Y; Miyajima M; Shudo C; Tanaka S; Shigenobu K; Kasuya Y
Gen Pharmacol; 1995 Mar; 26(2):339-45. PubMed ID: 7590084
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological in vitro studies of the new 1,4-dihydropyridine calcium antagonist lercanidipine.
Guarneri L; Angelico P; Ibba M; Poggesi E; Taddei C; Leonardi A; Testa R
Arzneimittelforschung; 1996 Jan; 46(1):15-24. PubMed ID: 8821512
[TBL] [Abstract][Full Text] [Related]
10. Comparison of binding affinities and negative inotropic potencies of the 1,4-dihydropyridine calcium channel blockers in rabbit myocardium.
Boyd RA; Giacomini JC; Wong FM; Nelson WL; Giacomini KM
J Pharmacol Exp Ther; 1987 Oct; 243(1):118-25. PubMed ID: 2822893
[TBL] [Abstract][Full Text] [Related]
11. MPC-1304, another type of dihydropyridine, possessing highly potent vasodilating action.
Miyoshi K; Kanda A; Miyake H; Ichihara K; Kamei H; Nagasaka M
Eur J Pharmacol; 1993 Jul; 238(2-3):139-48. PubMed ID: 7691619
[TBL] [Abstract][Full Text] [Related]
12. Binding properties of (+/-)[3H]benidipine hydrochloride to rat heart membranes.
Ishii A; Toyama J
J Cardiovasc Pharmacol; 1993 Feb; 21(2):191-6. PubMed ID: 7679151
[TBL] [Abstract][Full Text] [Related]
13. Active conformation of 1,4-dihydropyridine calcium entry blockers. Effect of size of 2-aryl substituent on rotameric equilibria and receptor binding.
Rovnyak G; Andersen N; Gougoutas J; Hedberg A; Kimball SD; Malley M; Moreland S; Porubcan M; Pudzianowski A
J Med Chem; 1991 Aug; 34(8):2521-4. PubMed ID: 1652021
[TBL] [Abstract][Full Text] [Related]
14. A new Ca-antagonist, CD-349, binding to the Ca-channel of rat myocardium and brain and hog coronary artery.
Muramatsu M; Fujita-Tominaga A; Tanaka M; Ishii Y; Aihara H
Jpn J Pharmacol; 1988 Dec; 48(4):453-62. PubMed ID: 2854176
[TBL] [Abstract][Full Text] [Related]
15. Inhibitory effect of NZ-105, a 1,4-dihydropyridine derivative, on cyclic nucleotide phosphodiesterase activity.
Yamashita T; Masuda Y; Sakai T; Tanaka S; Kasuya Y
J Pharm Pharmacol; 1993 Jun; 45(6):530-4. PubMed ID: 7689649
[TBL] [Abstract][Full Text] [Related]
16. Kinetics of binding of dihydropyridine calcium channel ligands to skeletal muscle membranes: evidence for low-affinity sites and for the involvement of G proteins.
Dunn SM; Bladen C
Biochemistry; 1991 Jun; 30(23):5716-21. PubMed ID: 1645998
[TBL] [Abstract][Full Text] [Related]
17. Interaction of pinaverium (a quaternary ammonium compound) with 1,4-dihydropyridine binding sites in rat ileum smooth muscle.
Feron O; Wibo M; Christen MO; Godfraind T
Br J Pharmacol; 1992 Feb; 105(2):480-4. PubMed ID: 1313732
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms underlying the slow onset of action of a new dihydropyridine, NZ-105, on a cultured smooth muscle cell line.
Tamura T; Saigusa A; Kokubun S
Naunyn Schmiedebergs Arch Pharmacol; 1991 Apr; 343(4):405-10. PubMed ID: 1649411
[TBL] [Abstract][Full Text] [Related]
19. Effect of S-312, a new calcium channel blocker, on the 1,4-dihydropyridine binding sites in porcine basilar blood vessels and rat aortic smooth muscle cells.
Mihara S; Fujimoto M
Jpn J Pharmacol; 1991 Jul; 56(3):249-59. PubMed ID: 1832726
[TBL] [Abstract][Full Text] [Related]
20. Contribution of aranidipine metabolites with slow binding kinetics to the vasodilating activity of aranidipine.
Miyoshi K; Miyake H; Ichihara K; Kamei H; Nagasaka M
Naunyn Schmiedebergs Arch Pharmacol; 1997 Jan; 355(1):119-25. PubMed ID: 9007851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
